- $317.77bn
- $361.24bn
- $65.01bn
Kelun, Merck's lung cancer combo improves survival in late-stage China trial (updated)
Brief: Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Factbox: Bundibugyo Ebola vaccines and treatments in development
Brief: National Advertising Review Board Refers Merck Animal Health To FTC & FDA For Bravecto Quantum Dosing Claims
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Health experts meet in search of Ebola Bundibugyo vaccine options (updated)
Ebola deaths in eastern Congo rise to 131 as outbreak spreads (updated)
International health experts meet in search for Ebola Bundibugyo vaccine options
Explainer: What do we know about the Bundibugyo strain of the Ebola virus?
Regeneron drops after skin cancer treatment misses late-stage trial goal (updated)
Merck's uterine cancer drug meets late-stage trial goals (updated)
Merck's endometrial cancer drug meets late-stage trial goals
Brief: Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoints Of Overall Survival And Progression-Free Survival In Certain Patients With Advanced Or Recurrent Endometrial Cancer
Regeneron drops after skin cancer treatment misses late-stage trial goal
Regeneron slides after skin cancer drug combo misses trial goal
FDA drug center head expected to leave after commissioner's exit, sources say
Brief: Mubadala Investment Co Pjsc Reports Share Stake In Apple, Medtronic, Broadcom